Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 42 of 648 for:    test AND point-of-care

Validation of POC-CCA Rapid Urine Test for Qualitative Detection of Schistosoma Japonicum (SchisCCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03870204
Recruitment Status : Not yet recruiting
First Posted : March 12, 2019
Last Update Posted : March 12, 2019
Sponsor:
Collaborators:
National Institute of Health Research and Development (NIHRD), Indonesia
The National Institute of Allergy and Infectious Diseases, United States
Information provided by (Responsible Party):
Ina-Respond

Tracking Information
First Submitted Date March 8, 2019
First Posted Date March 12, 2019
Last Update Posted Date March 12, 2019
Estimated Study Start Date July 1, 2019
Estimated Primary Completion Date June 30, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: March 8, 2019)
To estimate the accuracy of the schistosomiasis point-of-care circulating cathodic antigen (POC CCA) urine test for monitoring Schistosoma japonicum infection [ Time Frame: 1 year ]
  • Sensitivity will be established as the proportion of positives that are correctly identified by the POC-CCA rapid urine test, when compared to the Reference Method.
  • Specificity will be established as the proportion of negatives that are correctly identified by the POC-CCA rapid urine test, when compared to the Reference Method.
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: March 8, 2019)
  • To update existing epidemiologic, risk factor and mapping of human, snail and animal infections. [ Time Frame: 1 year ]
    Updated epidemiologic data (prevalence, age and sex distribution of schistosomiasis cases), risk factor and mapping of human, snail and animal infections.
  • To identify high infection risk areas with the updated data [ Time Frame: 1 year ]
    Using device (GPS/GIS) to record the location of source workplace, school, source of water and other risk factors related to human shistosome infections
  • To assess correlations between spatial parameters and other risk factors related to human schistosome infections. [ Time Frame: 1 year ]
    Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of the POC-CCA rapid urine test.
  • To assess rates of positive testing by POC-CCA rapid urine test, Kato Katz stool microscopies, serology, and molecular methods (PCR) [ Time Frame: 1 year ]
    Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of the POC-CCA rapid urine test.
  • To evaluate the impact of abnormal urinary findings, i.e. hematuria and markers of urinary tract infections, to POC-CCA rapid urine test results. [ Time Frame: 1 year ]
    Sensitivity and specificity of the POC-CCA rapid urine test, when compared to the Reference Method, among individuals with abnormal urinary findings.
  • To evaluate the efficacy of praziquantel administered through local primary health centers (Puskesmas). [ Time Frame: 1 year ]
    Evaluation of cure rate (percentage negative) after praziquantel administration to positive cases by either POC-CCA rapid urine test and/or Kato Katz multiple stool microscopies.
  • To estimate the prevalence of soil transmitted helminths infection (STH), i.e. roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura), and hookworms (Necator americanus and Ancylostoma duodenale) in this population. [ Time Frame: 1 year ]
    Prevalence of soil transmitted helminth infections.
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Validation of POC-CCA Rapid Urine Test for Qualitative Detection of Schistosoma Japonicum
Official Title Validation of the Schistosomiasis Point-of-Care Circulating Cathodic Antigen (POC-CCA) Rapid Urine Test for Qualitative Detection of Schistosoma Japonicum
Brief Summary This is a longitudinal cohort study to estimate the accuracy of the schistosomiasis point-of-care circulating cathodic antigen (POC CCA) urine test for monitoring S. japonicum infection by enrolling individuals aged ≥2 years living in the selected households will be invited to participate in the study (pediatric <18 years old will be invited through their parent/guardian) at Lindu, Napu and Bada regions of Central Sulawesi of highest S. japonicum infection prevalence. This study will be conducted in two stages, in the first stage, participants will be recruited from 10 villages of highest S. japonicum infection prevalence. A futility analysis will be conducted after stage one. If a decision is made to proceed with stage 2, additional participants will be recruited.
Detailed Description

Indonesia's plan for elimination of schistosomiasis by 2025 requires a better understanding of the factors associated with infection, effective epidemiologic monitoring, and optimization of diagnostic and treatment strategies. In settings of low prevalence such as Lindu, Napu and Bada regions of Central Sulawesi, an ultrasensitive technique to diagnose Schistosoma japonicum is needed. A diagnostic test that is efficient, accurate and easy to use would facilitate collection of reliable epidemiologic information and provide and effective means of assessing the impact of mass drug administration (MDA).

Primary Objective:

To estimate the accuracy of the schistosomiasis point-of-care circulating cathodic antigen (POC CCA) urine test for monitoring S. japonicum infection.

Secondary Objective

  1. To update existing epidemiologic, risk factor and mapping of human, snail and animal infections.
  2. To identify high infection risk areas with the updated data.
  3. To assess correlations between spatial parameters and other risk factors related to human schistosome infections.
  4. To assess rates of positive testing by POC-CCA rapid urine test, Kato Katz stool microscopies, serology, and molecular methods (PCR).
  5. To evaluate the impact of abnormal urinary findings, i.e. hematuria and markers of urinary tract infections, on POC-CCA rapid urine test results.
  6. To evaluate the efficacy of praziquantel administered through local primary health centers (Puskesmas).
  7. To estimate the prevalence of soil transmitted helminth infections (STH), i.e. roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura), and hookworms (Necator americanus and Ancylostoma duodenale) in this population.

If the target enrollment includes 30 infected participants by Kato Katz multiple stool microscopies, with the assumption of 0.3% prevalence and estimated precision of ±15-20%, up to 10,000 participants will be needed.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
Urine and stool at visit 1 and 3
Sampling Method Probability Sample
Study Population Schistosomiasis affected areas are in Lindu, Napu and Bada Valley of Central Sulawesi, Indonesia.
Condition Aged ≥2 Years in Schistosomiasis Affected Areas
Intervention Diagnostic Test: POC-CCA rapid urine test
Fresh urine samples will be tested by POC-CCA
Other Name: Kato-Katz, ELISA, and PCR
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: March 8, 2019)
10000
Original Estimated Enrollment Same as current
Estimated Study Completion Date July 31, 2020
Estimated Primary Completion Date June 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Reside in schistosomiasis affected areas for at least 8 weeks.
  • Age ≥2 years.
  • Provides a documented informed consent for participants' ≥18 years old or informed consent by parents/legally accepted representative (LAR) or assent for minor participants prior to the study procedures.
  • Willing to comply with the study procedures.
  • Agrees to the collection and storage of specimens.

Exclusion Criteria:

None.

Sex/Gender
Sexes Eligible for Study: All
Ages 2 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Muhammad Karyana, dr. MKes +622142879189 mkaryana@ina-respond.net
Contact: Dona Arlinda, dr. +622142879189 arlindona@ina-respond.net
Listed Location Countries Indonesia
Removed Location Countries  
 
Administrative Information
NCT Number NCT03870204
Other Study ID Numbers INA105
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Plan Description: Currently we not have any plan to share IPD.
Responsible Party Ina-Respond
Study Sponsor Ina-Respond
Collaborators
  • National Institute of Health Research and Development (NIHRD), Indonesia
  • The National Institute of Allergy and Infectious Diseases, United States
Investigators
Principal Investigator: Muhammad Karyana, dr. MKes Ina-Respond
PRS Account Ina-Respond
Verification Date March 2019